Implementation of a novel microarray‐based diagnostic test for cancer of unknown primary
Open Access
- 14 July 2009
- journal article
- early detection-and-diagnosis
- Published by Wiley in International Journal of Cancer
- Vol. 125 (6) , 1390-1397
Abstract
Patients with carcinoma of unknown primary (CUP) present with metastatic disease for which the primary site cannot be found, despite extensive standard investigation. Here, we describe the development and implementation of the first clinically available microarray‐based test for this cancer type (CUPPrint), based on 633 individual tumors representing 30 carcinoma and 17 noncarcinoma classes. Tissue of origin prediction for either fresh frozen or paraffin‐embedded tumor samples is achieved with the use of a custom 8‐pack 1.9k microarray and robust classification algorithm. An expression profile of 495 genes was used to predict tumor origin by applying a k‐nearest neighbor algorithm. Internal cross‐validation and analysis of an independent, previously published, 229‐sample dataset revealed that clinically informative predictions were made for up to 94% of samples analyzed. Analysis of 13 previously published CUP specimens yielded predicted tumor origins that supported the clinical suspicion in 12 cases (92%). Microarray profiling presents a promising tool to assist in the identification of the primary tumor and might direct a more tailored treatment for CUP patients. © 2009 UICCKeywords
This publication has 30 references indexed in Scilit:
- Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown PrimaryJournal of Clinical Oncology, 2008
- Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primaryBritish Journal of Cancer, 2008
- MicroRNAs accurately identify cancer tissue originNature Biotechnology, 2008
- Interlaboratory Performance of a Microarray-Based Gene Expression Test to Determine Tissue of Origin in Poorly Differentiated and Undifferentiated CancersThe Journal of Molecular Diagnostics, 2008
- Switching benchmarks in cancer of unknown primary: From autopsy to microarrayEuropean Journal of Cancer, 2007
- ErbB‐4 may control behavior of prostate cancer cells and serve as a target for molecular therapyThe Prostate, 2007
- Cancer of Unknown Primary Site: Missing Primary or Missing Biology?The Oncologist, 2007
- An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown OriginCancer Research, 2005
- Molecular target-based cancer therapy: tyrosine kinase inhibitorsInternational Journal of Clinical Oncology, 2003
- Tissue Classification with Gene Expression ProfilesJournal of Computational Biology, 2000